DOCSLIB.ORG

The Role of Methionine Aminopeptidase 2 in Lymphangiogenesis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Role of Methionine Aminopeptidase 2 in Lymphangiogenesis International Journal of Molecular Sciences Article The Role of Methionine Aminopeptidase 2 in Lymphangiogenesis 1, 1, 1, 1 2 Rawnaq Esa y, Eliana Steinberg y, Dvir Dror y, Ouri Schwob , Mehrdad Khajavi , Miriam Maoz 3, Yael Kinarty 4, Adi Inbal 4 , Aviad Zick 3 and Ofra Benny 1,* 1 The Institute for Drug Research, The School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel; [email protected] (R.E.); [email protected] (E.S.); [email protected] (D.D.); [email protected] (O.S.) 2 Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA; [email protected] 3 Sharett Institute of Oncology, Hebrew University-Hadassah Medical Center, Jerusalem 91120, Israel; [email protected] (M.M.); [email protected] (A.Z.) 4 Department of Medical Neurobiology, Institute for Medical Research—Israel-Canada, The Hebrew University of Jerusalem, Hadassah Medical School, Jerusalem 9112002, Israel; [email protected] (Y.K.); [email protected] (A.I.) * Correspondence: [email protected]; Tel.: +972-2-6757268 These authors contributed equally to this work. y Received: 18 June 2020; Accepted: 16 July 2020; Published: 21 July 2020 Abstract: During the metastasis process, tumor cells invade the blood circulatory system directly from venous capillaries or indirectly via lymphatic vessels. Understanding the relative contribution of each pathway and identifying the molecular targets that affect both processes is critical for reducing cancer spread. Methionine aminopeptidase 2 (MetAp2) is an intracellular enzyme known to modulate angiogenesis. In this study, we investigated the additional role of MetAp2 in lymphangiogenesis. A histological staining of tumors from human breast-cancer donors was performed in order to detect the level and the localization of MetAp2 and lymphatic capillaries. The basal enzymatic level and activity in vascular and lymphatic endothelial cells were compared, followed by loss of function studies determining the role of MetAp2 in lymphangiogenesis in vitro and in vivo. The results from the histological analyses of the tumor tissues revealed a high MetAp2 expression, with detectable sites of co-localization with lymphatic capillaries. We showed slightly reduced levels of the MetAp2 enzyme and MetAp2 mRNA expression and activity in primary lymphatic cells when compared to the vascular endothelial cells. The genetic and biochemical manipulation of MetAp2 confirmed the dual activity of the enzyme in both vascular and lymphatic remodulation in cell function assays and in a zebrafish model. We found that cancer-related lymphangiogenesis is inhibited in murine models following MetAp2 inhibition treatment. Taken together, our study provides an indication that MetAp2 is a significant contributor to lymphangiogenesis and carries a dual role in both vascular and lymphatic capillary formation. Our data suggests that MetAp2 inhibitors can be effectively used as anti-metastatic broad-spectrum drugs. Keywords: MetAp2; angiogenesis; lymphangiogenesis; metastasis; cancer 1. Introduction Cancer metastasis is associated with a high mortality rate and is the primary cause of cancer morbidity. The spread of tumor cells from their primary origin occurs mainly via blood and lymphatic vessels [1]. The 3-dimensional (3D) fast growth of tumors creates a dynamic microenvironment with Int. J. Mol. Sci. 2020, 21, 5148; doi:10.3390/ijms21145148 www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2020, 21, 5148 2 of 15 elevated demands for nutrients and oxygen exchange as well as metabolic waste disposal which are accommodated by the expedited angiogenesis process [2,3]. Angiogenesis is regulated by a dynamic balance between inducer and inhibitor molecules. Tumor angiogenesis is a multistep process triggered by diverse factors secreted by the hypoxic tumor as well as by the host cells [4]. This process is characterized by a formation of new blood vessels from pre-existing vessels [2,3]. Similar to angiogenesis, the growth and formation of new lymphatic vessels, known as lymphangiogenesis, occurs in response to multiple triggers [5]. Lymphangiogenesis was shown to play a critical role in tumor progression and metastasis [6]. Unlike hematologic vessels, lymphatic vessels are thin and consist of discontinuous membranes that enable the penetration of tumor cells into the lymphatic circulation and the adjacent capillary lumens. In response to secreted signals, both lymphatic and vascular endothelial cells proliferate and migrate toward the stimulus, assembling into tube-like structures [1]. Several pathways were identified as promoting angiogenesis and lymphangiogenesis, the most studied and dominant one being the vascular endothelial growth factor (VEGF) pathway. VEGF, which is overexpressed in most cancers and functions as a crucial regulator in angiogenesis and lymphangiogenesis [3,7–9], has become an important target for inhibiting tumor metastasis. Among the various VEGF family members, VEGF-C and VEGF-D are secreted by the tumor and stromal cells, playing a dominant role in mediating tumor-related lymphangiogenesis [6,10–12]. However, there are many additional mediators that are involved in capillary formation and remodeling. Among these mediators is MetAp2, which belongs to a family of post-translational modification enzymes, acting downstream to VEGF. There are two forms of MetAp in eukaryotes: MetAp1 and MetAp2, the latter having received more interest. This is because the induction of Metap2 was shown to mediate cell proliferation and lead to G1 arrest when inhibited [13–17], since it affects protein synthesis via the post-translation removal of methionine [18–21]. Given MetAp2’s major role in protein synthesis in activated vascular endothelial cells, we hypothesize that MetAp2 also affects lymphangiogenesis by mediating the lymphatic endothelium formation via shared mechanisms. In patient-derived breast cancer tissues, we found that MetAp2 is expressed and co-localized with lymphatic vessels. At the cellular level, we found that the basal expressions of MetAp2 and its activities in human lymphatic endothelial cells (LECs) versus vascular endothelial cells (VECs) were comparable, with slightly higher levels in VECs. In functionality assays including cell proliferation, adhesion, and tube formation, LECs showed suppression upon exposure to TNP-470, a MetAp2 inhibitor. In vivo, in a non-cancerous context using the zebrafish developmental model, the specific inhibition of MetAp2 led to a significant reduction in the development of lymphatic vessels. Parachordal cells (PACs), which make up the lymphatic vessels, were observed in only 0.76 out of 3 segments after treatment with 500 µM of the MetAp2 inhibitor. Moreover, in a subcutaneous (S.C.) murine model using B16/F10 melanoma tumors overexpressing VEGF-C, systemic treatment with 30 mg/kg q.o.d induced over a 50% reduction in the tumors’ volume. A histological examination of the tumors suggested an associated dual reduction of angiogenesis and lymphangiogenesis induced by MetAp2 inhibition. Taken together, our data suggest that MetAp2 is a mediator of both angiogenesis and lymphangiogenesis and that its inhibition may slow cancer progression and metastasis. 2. Results 2.1. MetAp2 Expression and Activity in LECs and Tissues Human tumor tissues were surgically resected and collected from breast cancer patients for the histological examination and detection of lymphatic endothelium (indicated by LYVE1 expression) as well as MetAp2 expression. The immunofluorescent staining of the tissue sections showed both MetAp2 and LYVE1 expression with a few loci sites of co-localization (Figure1A,B). Int. J. Mol. Sci. 2020, 21, 5148 3 of 15 Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 15 of 15 Figure 1. Cancer tissue samples retrieved from two breast cancer patients express MetAp2 and LYVE1. (AFigure,B) Immunofluorescence 1. Cancer tissue samples staining ofretrieved MetAp2 from (red), two LYVE1 breast (green), cancer and patients DAPI (blue) express reveal MetAp2 lymphatic and structuresLYVE1. (A co-localized,B) Immunofluorescence with MetAp2 staining expression. of MetAp2 Black and (red), white LYVE1 images (green), represent and DAPI fluorescence (blue) reveal in a singlelymphatic channel. structures Left panel co-localized scale bar = with100 µ m.MetAp2 Right panelexpression. scale bar Black= 20–50 andµ whitem. images represent fluorescence in a single channel. Left panel scale bar = 100 µm. Right panel scale bar = 20-50 µm. Immunoblotting and quantitative real-time PCR (qRT-PCR) were used to measure protein expressionImmunoblotting at the cell-level. andThe quantitative basal cellular real-time protein PC levelsR (qRT-PCR) (baseline expressionwere used in to the measure activated protein state ofexpression cells grown at inthe optimal cell-level. growth The conditions)basal cellular of MetAp2protein levels were comparable(baseline expression in both the in vascular the activated and lymphaticstate of cells endothelial grown in cellsoptimal (VECs growth and LECs,conditions) respectively), of MetAp2 with were slightly comparable higher in levels both ofthe MetAp2 vascular inand the lymphatic vascular endothelium endothelial (Figurecells (VECs2A). Inand addition, LECs, qRT-PCRrespectively), was usedwith toslightly quantify higher the MetAp2levels of mRNAMetAp2 levels in the in human vascular umbilical endothelium vein endothelial (Figure 2A). cells In (HUVECs) addition, andqRT-PCR in human was dermal
Load more

Recommended publications
  • Supplementary Materials: Evaluation of Cytotoxicity and Α-Glucosidase Inhibitory Activity of Amide and Polyamino-Derivatives of Lupane Triterpenoids
    Supplementary Materials: Evaluation of cytotoxicity and α-glucosidase inhibitory activity of amide and polyamino-derivatives of lupane triterpenoids Oxana B. Kazakova1*, Gul'nara V. Giniyatullina1, Akhat G. Mustafin1, Denis A. Babkov2, Elena V. Sokolova2, Alexander A. Spasov2* 1Ufa Institute of Chemistry of the Ufa Federal Research Centre of the Russian Academy of Sciences, 71, pr. Oktyabrya, 450054 Ufa, Russian Federation 2Scientific Center for Innovative Drugs, Volgograd State Medical University, Novorossiyskaya st. 39, Volgograd 400087, Russian Federation Correspondence Prof. Dr. Oxana B. Kazakova Ufa Institute of Chemistry of the Ufa Federal Research Centre of the Russian Academy of Sciences 71 Prospeсt Oktyabrya Ufa, 450054 Russian Federation E-mail: [email protected] Prof. Dr. Alexander A. Spasov Scientific Center for Innovative Drugs of the Volgograd State Medical University 39 Novorossiyskaya st. Volgograd, 400087 Russian Federation E-mail: [email protected] Figure S1. 1H and 13C of compound 2. H NH N H O H O H 2 2 Figure S2. 1H and 13C of compound 4. NH2 O H O H CH3 O O H H3C O H 4 3 Figure S3. Anticancer screening data of compound 2 at single dose assay 4 Figure S4. Anticancer screening data of compound 7 at single dose assay 5 Figure S5. Anticancer screening data of compound 8 at single dose assay 6 Figure S6. Anticancer screening data of compound 9 at single dose assay 7 Figure S7. Anticancer screening data of compound 12 at single dose assay 8 Figure S8. Anticancer screening data of compound 13 at single dose assay 9 Figure S9. Anticancer screening data of compound 14 at single dose assay 10 Figure S10.
    [Show full text]
  • The Global Architecture Shaping the Heterogeneity and Tissue-Dependency of the MHC Class I Immunopeptidome Is Evolutionarily Conserved
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.28.317750; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The Global Architecture Shaping the Heterogeneity and Tissue-Dependency of the MHC Class I Immunopeptidome is Evolutionarily Conserved Authors Peter Kubiniok†1, Ana Marcu†2,3, Leon Bichmann†2,4, Leon Kuchenbecker4, Heiko Schuster1,5, David Hamelin1, Jérome Despault1, Kevin Kovalchik1, Laura Wessling1, Oliver Kohlbacher4,7,8,9,10 Stefan Stevanovic2,3,6, Hans-Georg Rammensee2,3,6, Marian C. Neidert11, Isabelle Sirois1, Etienne Caron1,12* Affiliations *Corresponding and Leading author: Etienne Caron ([email protected]) †Equal contribution to this work 1CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada 2Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Baden-Württemberg, 72076, Germany. 3Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Baden-Württemberg, 72076, Germany. 4Applied Bioinformatics, Dept. of Computer Science, University of Tübingen, Tübingen, Baden- Württemberg, 72074, Germany. 5Immatics Biotechnologies GmbH, Tübingen, 72076, Baden-Württemberg, Germany. 6DKFZ Partner Site Tübingen, German Cancer Consortium (DKTK), Tübingen, Baden- Württemberg, 72076, Germany. 7Institute for Bioinformatics and Medical Informatics,
    [Show full text]
  • Sequences in the Cytoplasmic Tail of SARS-Cov-2 Spike Facilitate Expression at the Cell Surface and Syncytia Formation
    bioRxiv preprint doi: https://doi.org/10.1101/2020.10.12.335562; this version posted May 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate expression at the cell surface and syncytia formation Jerome Cattin-Ortolá1,2, Lawrence Welch1,2, Sarah L. Maslen1, J. Mark Skehel1, Guido Papa1, Leo C. James1 and Sean Munro1* 1: MRC Laboratory oF Molecular Biology Francis Crick Avenue Cambridge CB2 0QH UK 2: Denotes equal contribution * Corresponding author: Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.10.12.335562; this version posted May 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract The Spike (S) protein of SARS-CoV-2 binds ACE2 to direct fusion with host cells. S comprises a large external domain, a transmembrane domain (TMD) and a short cytoplasmic tail. Understanding the intracellular trafficking of S is relevant to SARS-CoV-2 infection, and to vaccines expressing full-length S from mRNA or adenovirus vectors. We have applied proteomics to identify cellular factors that interact with the cytoplasmic tail of S.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Elucidation of the Function of Type 1 Human Methionine Aminopeptidase During Cell Cycle Progression
    Elucidation of the function of type 1 human methionine aminopeptidase during cell cycle progression Xiaoyi Hu*, Anthony Addlagatta†, Jun Lu*, Brian W. Matthews†‡, and Jun O. Liu*‡§ *Department of Pharmacology and Molecular Sciences and §Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205; and †Institute of Molecular Biology, Howard Hughes Medical Institute and Department of Physics, University of Oregon, Eugene, OR 97403-1229 Contributed by Brian W. Matthews, October 4, 2006 (sent for review September 7, 2006) Processing of the N-terminal initiator methionine is an essential notion that HsMetAP2 plays an important role in endothelial cell cellular process conserved from prokaryotes to eukaryotes. The proliferation and is likely to mediate inhibition of endothelial cells enzymes that remove N-terminal methionine are known as methi- by fumagillin and related analogs (5, 6, 9). onine aminopeptidases (MetAPs). Human MetAP2 has been shown In contrast to HsMetAP2, little is known about the physiological to be required for the proliferation of endothelial cells and angio- function of human MetAP1, although genetic studies in yeast have genesis. The physiological function of MetAP1, however, has suggested a more dominant role for ScMetAP1, as evidenced by the remained elusive. In this report we demonstrate that a family of more severe growth defect observed in ScMetAP1 knockout strain inhibitors with a core structure of pyridine-2-carboxylic acid pre- than that in ScMetAP2 knockout strain (10). There has also been viously developed for the bacterial and yeast MetAP1 is also circumstantial evidence implicating a role of HsMetAP1 in tumor specific for human MetAP1 (HsMetAP1), as confirmed by both cell proliferation.
    [Show full text]
  • Secreted Metalloproteinase ADAMTS-3 Inactivates Reelin
    The Journal of Neuroscience, March 22, 2017 • 37(12):3181–3191 • 3181 Cellular/Molecular Secreted Metalloproteinase ADAMTS-3 Inactivates Reelin Himari Ogino,1* Arisa Hisanaga,1* XTakao Kohno,1 Yuta Kondo,1 Kyoko Okumura,1 Takana Kamei,1 Tempei Sato,2 Hiroshi Asahara,2 Hitomi Tsuiji,1 Masaki Fukata,3 and Mitsuharu Hattori1 1Department of Biomedical Science, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi 467-8603, Japan, 2Department of Systems BioMedicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan, and 3Division of Membrane Physiology, Department of Molecular and Cellular Physiology, National Institute for Physiological Sciences, National Institutes of Natural Sciences, Okazaki, Aichi 444-8787, Japan The secreted glycoprotein Reelin regulates embryonic brain development and adult brain functions. It has been suggested that reduced Reelin activity contributes to the pathogenesis of several neuropsychiatric and neurodegenerative disorders, such as schizophrenia and Alzheimer’s disease; however, noninvasive methods that can upregulate Reelin activity in vivo have yet to be developed. We previously found that the proteolytic cleavage of Reelin within Reelin repeat 3 (N-t site) abolishes Reelin activity in vitro, but it remains controversial as to whether this effect occurs in vivo. Here we partially purified the enzyme that mediates the N-t cleavage of Reelin from the culture supernatant of cerebral cortical neurons. This enzyme was identified as a disintegrin and metalloproteinase with thrombospondin motifs-3 (ADAMTS-3). Recombinant ADAMTS-3 cleaved Reelin at the N-t site. ADAMTS-3 was expressed in excitatory neurons in the cerebral cortex and hippocampus.
    [Show full text]
  • What Is a Protease?
    What is a Protease? Proteases (or peptidases) are enzymes secreted by animals for a number of physiological processes, among which is the Dr. Rolando A. Valientes digestion of feed protein. Regional Category Manager- Animals normally secrete suffi - Eubiotics / RONOZYME ProAct cient amount of enzymes to ade - Asia Pacific, DSM quately digest enough of their [email protected] feed so that they grow and remain healthy under normal conditions, such as those found in the wild. Any increased needs for protein (amino acids) for more rapid growth due to improved genetics has been traditionally met by adding more protein (or synthetic amino acids) into the feed. This was facilitated by a relative low cost for most protein-rich ingredi - Dr. Katrine Pontoppidan ents, such as soybean meal, and Research Scientist synthetic amino acids, such as Novozymes L-lysine HCL. Thus, an exogenous [email protected] protease (as a feed supplement) was not considered essential; that is, until recently. size, the rate of passage of feed Today we face not only the prob - through the digestive tract, the lem of feeding animals of continu - age of the animal, and its physio - ously increasing genetic potential logical/health condition. All of (this requires diets increasingly these variables are rather difficult richer in amino acids), but also an to control, but supplementing unprecedented rise in ingredient animal feeds with extra enzymes prices, leaving very small (if any) is rather easy if it can be done in a margin for profitability. Thus, it profitable way. has been deemed essential to seek ways to improve the nutritive Up until recently, any protease value of existing ingredients activity in commercial enzyme reducing feed cost.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • The Involvement of Cysteine Proteases and Protease Inhibitor Genes in the Regulation of Programmed Cell Death in Plants
    The Plant Cell, Vol. 11, 431–443, March 1999, www.plantcell.org © 1999 American Society of Plant Physiologists The Involvement of Cysteine Proteases and Protease Inhibitor Genes in the Regulation of Programmed Cell Death in Plants Mazal Solomon,a,1 Beatrice Belenghi,a,1 Massimo Delledonne,b Ester Menachem,a and Alex Levine a,2 a Department of Plant Sciences, Hebrew University of Jerusalem, Givat-Ram, Jerusalem 91904, Israel b Istituto di Genetica, Università Cattolica S.C., Piacenza, Italy Programmed cell death (PCD) is a process by which cells in many organisms die. The basic morphological and bio- chemical features of PCD are conserved between the animal and plant kingdoms. Cysteine proteases have emerged as key enzymes in the regulation of animal PCD. Here, we show that in soybean cells, PCD-activating oxidative stress in- duced a set of cysteine proteases. The activation of one or more of the cysteine proteases was instrumental in the PCD of soybean cells. Inhibition of the cysteine proteases by ectopic expression of cystatin, an endogenous cysteine pro- tease inhibitor gene, inhibited induced cysteine protease activity and blocked PCD triggered either by an avirulent strain of Pseudomonas syringae pv glycinea or directly by oxidative stress. Similar expression of serine protease inhib- itors was ineffective. A glutathione S-transferase–cystatin fusion protein was used to purify and characterize the in- duced proteases. Taken together, our results suggest that plant PCD can be regulated by activity poised between the cysteine proteases and the cysteine protease inhibitors. We also propose a new role for proteinase inhibitor genes as modulators of PCD in plants.
    [Show full text]
  • Methionine Aminopeptidase Emerging Role in Angiogenesis
    Chapter 2 Methionine Aminopeptidase Emerging role in angiogenesis Joseph A. Vetro1, Benjamin Dummitt2, and Yie-Hwa Chang2 1Department of Pharmaceutical Chemistry, University of Kansas, 2095 Constant Ave., Lawrence, KS 66047, USA. 2Edward A. Doisy Department of Biochemistry and Molecular Biology, St. Louis University Health Sciences Center, 1402 S. Grand Blvd., St. Louis, MO 63104, USA. Abstract: Angiogenesis, the formation of new blood vessels from existing vasculature, is a key factor in a number of vascular-related pathologies such as the metastasis and growth of solid tumors. Thus, the inhibition of angiogenesis has great potential as a therapeutic modality in the treatment of cancer and other vascular-related diseases. Recent evidence suggests that the inhibition of mammalian methionine aminopeptidase type 2 (MetAP2) catalytic activity in vascular endothelial cells plays an essential role in the pharmacological activity of the most potent small molecule angiogenesis inhibitors discovered to date, the fumagillin class. Methionine aminopeptidase (MetAP, EC 3.4.11.18) catalyzes the non-processive, co-translational hydrolysis of initiator N-terminal methionine when the second residue of the nascent polypeptide is small and uncharged. Initiator Met removal is a ubiquitous and essential modification. Indirect evidence suggests that removal of initiator Met by MetAP is important for the normal function of many proteins involved in DNA repair, signal transduction, cell transformation, secretory vesicle trafficking, and viral capsid assembly and infection. Currently, much effort is focused on understanding the essential nature of methionine aminopeptidase activity and elucidating the role of methionine aminopeptidase type 2 catalytic activity in angiogenesis. In this chapter, we give an overview of the MetAP proteins, outline the importance of initiator Met hydrolysis, and discuss the possible mechanism(s) through which MetAP2 inhibition by the fumagillin class of angiogenesis inhibitors leads to cytostatic growth arrest in vascular endothelial cells.
    [Show full text]
  • Arxiv:2007.15681V2 [Cs.CL] 9 Nov 2020 Method by a Large Margin
    COVID-19 therapy target discovery with context-aware literature mining Matej Martinc1;2, Blaˇz Skrljˇ 1;2, Sergej Pirkmajer3, Nada Lavraˇc1;2;4, Bojan Cestnik5;1, Martin Marzidovˇsek1;2, and Senja Pollak2 1 JoˇzefStefan International Postgraduate School, Ljubljana, Slovenia 2 JoˇzefStefan Institute, Ljubljana, Slovenia 3 Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia 4 University of Nova Gorica, Vipava, Slovenia 5 Temida d.o.o, Ljubljana, Slovenia The final reviewed publication was published in Proceedings of the 23rd International Conference on Discovery Science (DS 2020), Thessaloniki, Greece, October 19{21, 2020 and is available online at https://doi.org/ 10.1007/978-3-030-61527-7 8. Abstract. The abundance of literature related to the widespread COVID- 19 pandemic is beyond manual inspection of a single expert. Develop- ment of systems, capable of automatically processing tens of thousands of scientific publications with the aim to enrich existing empirical evidence with literature-based associations is challenging and relevant. We propose a system for contextualization of empirical expression data by approxi- mating relations between entities, for which representations were learned from one of the largest COVID-19-related literature corpora. In order to exploit a larger scientific context by transfer learning, we propose a novel embedding generation technique that leverages SciBERT language model pretrained on a large multi-domain corpus of scientific publications and fine-tuned for domain adaptation on the CORD-19 dataset. The con- ducted manual evaluation by the medical expert and the quantitative evaluation based on therapy targets identified in the related work suggest that the proposed method can be successfully employed for COVID-19 therapy target discovery and that it outperforms the baseline FastText arXiv:2007.15681v2 [cs.CL] 9 Nov 2020 method by a large margin.
    [Show full text]
  • Supplementary Table 9. Functional Annotation Clustering Results for the Union (GS3) of the Top Genes from the SNP-Level and Gene-Based Analyses (See ST4)
    Supplementary Table 9. Functional Annotation Clustering Results for the union (GS3) of the top genes from the SNP-level and Gene-based analyses (see ST4) Column Header Key Annotation Cluster Name of cluster, sorted by descending Enrichment score Enrichment Score EASE enrichment score for functional annotation cluster Category Pathway Database Term Pathway name/Identifier Count Number of genes in the submitted list in the specified term % Percentage of identified genes in the submitted list associated with the specified term PValue Significance level associated with the EASE enrichment score for the term Genes List of genes present in the term List Total Number of genes from the submitted list present in the category Pop Hits Number of genes involved in the specified term (category-specific) Pop Total Number of genes in the human genome background (category-specific) Fold Enrichment Ratio of the proportion of count to list total and population hits to population total Bonferroni Bonferroni adjustment of p-value Benjamini Benjamini adjustment of p-value FDR False Discovery Rate of p-value (percent form) Annotation Cluster 1 Enrichment Score: 3.8978262119731335 Category Term Count % PValue Genes List Total Pop Hits Pop Total Fold Enrichment Bonferroni Benjamini FDR GOTERM_CC_DIRECT GO:0005886~plasma membrane 383 24.33290978 5.74E-05 SLC9A9, XRCC5, HRAS, CHMP3, ATP1B2, EFNA1, OSMR, SLC9A3, EFNA3, UTRN, SYT6, ZNRF2, APP, AT1425 4121 18224 1.18857065 0.038655922 0.038655922 0.086284383 UP_KEYWORDS Membrane 626 39.77128335 1.53E-04 SLC9A9, HRAS,
    [Show full text]